Ohta, K., Ichinose, M., Tohda, Y., Engel, M., Moroni-Zentgraf, P., Kunimitsu, S., . . . Adachi, M. (2015). Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study. PLoS One.

Ohta, Ken, Masakazu Ichinose, Yuji Tohda, Michael Engel, Petra Moroni-Zentgraf, Satoko Kunimitsu, Wataru Sakamoto, ja Mitsuru Adachi. "Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy Over 52 Weeks in Patients With Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study." PLoS One 2015.

Ohta, Ken, et al. "Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy Over 52 Weeks in Patients With Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study." PLoS One 2015.